Prime Medicine, Inc.
PRME
$1.27
-$0.07-5.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -202.01M | -195.88M | -219.25M | -217.44M | -204.50M |
| Total Depreciation and Amortization | 6.51M | 6.13M | 5.66M | 5.34M | 4.92M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.95M | 35.81M | 33.95M | 33.89M | 26.87M |
| Change in Net Operating Assets | 53.53M | 31.08M | -3.33M | -18.01M | -18.85M |
| Cash from Operations | -104.02M | -122.87M | -182.97M | -196.23M | -191.56M |
| Capital Expenditure | -7.39M | -7.29M | -7.34M | -8.98M | -9.05M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 65.14M | 75.75M | 68.83M | -17.65M | 3.39M |
| Cash from Investing | 57.75M | 68.46M | 61.49M | -26.62M | -5.66M |
| Total Debt Issued | 0.00 | 0.00 | 0.00 | 0.00 | 6.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 38.51M | 189.84M | 190.03M | 151.84M | 151.91M |
| Repurchase of Common Stock | -18.77M | -18.77M | -18.77M | -18.77M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 24.80M | 24.80M | 24.80M | 24.80M | -- |
| Cash from Financing | 44.55M | 195.88M | 196.07M | 157.87M | 157.91M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.72M | 141.47M | 74.58M | -64.98M | -39.30M |